{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:32:38Z","timestamp":1774949558422,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary pituitary lymphoma (PPL) is an extremely rare disease with poor prognosis. Although PPL has been shown to be different from classical primary central nervous system lymphoma because of the embryological origin of structures, individual and precise treatment of PPL remains unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 61-year-old man and a 65-year-old woman both diagnosed with primary pituitary diffuse large B cell lymphoma underwent genetic analysis of cerebrospinal fluid and tumor tissue by next generation sequencing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the first case, partial remission was achieved following R\u00b2-MTX chemotherapy. In the other case with <jats:italic>TP53<\/jats:italic> mutation and <jats:italic>BCL6<\/jats:italic>-<jats:italic>LPP<\/jats:italic> fusion, disease progressed although different chemotherapy regimens were given.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The gene mutation of <jats:italic>TP53<\/jats:italic> and <jats:italic>BCL6<\/jats:italic> may be identified as a marker responsible for prognostic difference in patients with PPL. Genetic analysis may provide a novel approach for precise management and prognosis prediction.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.673908","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T10:09:27Z","timestamp":1627294167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case Report: Identification of Potential Prognosis-Related TP53 Mutation and BCL6-LPP Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases"],"prefix":"10.3389","volume":"12","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2249-z","article-title":"Primary Pituitary Lymphoma: An Update of the Literature","volume":"130","author":"Tarabay","year":"2016","journal-title":"J Neurooncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.10.7909","article-title":"Clinical Review 136: Primary Lymphoma of the Pituitary: An Emerging Clinical Entity","volume":"86","author":"Giustina","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2598","article-title":"Primary Central Nervous System Lymphoma: A Curable Disease","author":"Batchelor","year":"2019","journal-title":"Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2018.0419","article-title":"The Diagnosis and Treatment of Primary Cns Lymphoma","volume":"115","author":"von Baumgarten","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and Treatment of Primary CNS Lymphoma in Immunocompetent Patients: Guidelines From the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00415-011-6179-6","article-title":"Primary Pituitary Lymphoma in an Immunocompetent Patient: A Rare Clinical Entity","volume":"259","author":"Li","year":"2012","journal-title":"J Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30838","article-title":"TP53 Mutation and Survival in Aggressive B Cell Lymphoma","volume":"141","author":"Zenz","year":"2017","journal-title":"Int J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13065","article-title":"Mutations or Copy Number Losses of CD58 and TP53 Genes in Diffuse Large B Cell Lymphoma Are Independent Unfavorable Prognostic Factors","volume":"7","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.path.2019.03.012","article-title":"Prognostic and Predictive Biomarkers in Diffuse Large B-Cell Lymphoma","volume":"12","author":"Chan","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24656","article-title":"TP53 and OSBPL10 Alterations in Diffuse Large B-Cell Lymphoma: Prognostic Markers Identified Via Exome Analysis of Cases With Extreme Prognosis","volume":"9","author":"Dobashi","year":"2018","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP: Report From an International Dlbcl Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0307-6","article-title":"TP53 Hotspot Mutations Are Predictive of Survival in Primary Central Nervous System Lymphoma Patients Treated With Combination Chemotherapy","volume":"4","author":"Munch-Petersen","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17050683","article-title":"Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses","volume":"17","author":"Todorovic Balint","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07739.x","article-title":"The Significance of TP53 in Lymphoid Malignancies: Mutation Prevalence, Regulation, Prognostic Impact and Potential as a Therapeutic Target","volume":"146","author":"Cheung","year":"2009","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12920-019-0484-9","article-title":"Clinical Aspects of TP53 Gene Inactivation in Diffuse Large B-Cell Lymphoma","volume":"12","author":"Voropaeva","year":"2019","journal-title":"BMC Med Genomics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290033305","article-title":"Non-Immunoglobulin\/BCL6 Gene Fusion in Diffuse Large B-Cell Lymphoma: Prognostic Implications","volume":"43","author":"Ueda","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/01.jnen.0000229988.48042.ae","article-title":"Chromosomal Translocations Fusing the BCL6 Gene to Different Partner Loci Are Recurrent in Primary Central Nervous System Lymphoma and May Be Associated With Aberrant Somatic Hypermutation or Defective Class Switch Recombination","volume":"65","author":"Schwindt","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.1455","article-title":"Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course","volume":"26","author":"Cady","year":"2008","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov046","article-title":"Prognostic Impact of B-Cell Lymphoma 6 in Primary CNS Lymphoma","volume":"17","author":"Kreher","year":"2015","journal-title":"Neuro Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12801","article-title":"LMO2 and BCL6 Are Associated With Improved Survival in Primary Central Nervous System Lymphoma","volume":"165","author":"Lossos","year":"2014","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13000-019-0833-1","article-title":"Treatment Outcome and Prognostic Factors in PCNSL","volume":"14","author":"Niparuck","year":"2019","journal-title":"Diagn Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt385","article-title":"Beyond High-Dose Methotrexate and Brain Radiotherapy: Novel Targets and Agents for Primary CNS Lymphoma","volume":"25","author":"Ponzoni","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.673908\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T10:09:31Z","timestamp":1627294171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.673908\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":22,"alternative-id":["10.3389\/fendo.2021.673908"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.673908","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"article-number":"673908"}}